Literature DB >> 11962513

The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C.

K A Hood1, B T Bäckström, L M West, P T Northcote, M V Berridge, J H Miller.   

Abstract

A novel secondary sponge metabolite, peloruside A (peloruside), isolated from the marine sponge Mycale sp. (New Zealand), was tested for its cytotoxic effects on mammalian cells in culture. The macrolide structure of peloruside is similar to that of the protein kinase C (PKC) activator, bryostatin-1 (bryostatin), both containing a pyranose ring adjacent to a gemdimethyl moiety. Peloruside is a potent inhibitor of cell proliferation. Treatment of different mammalian cell lines with peloruside for 48-96 h gave IC50 values ranging from 4 to 15 nM, using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium (MTT) cell proliferation assay. Peloruside was shown to be both cytostatic and cytotoxic by trypan blue dye exclusion tests. Peloruside induced apoptosis in a dose-dependent manner in murine (32D) and human (HL-60) myeloid cell lines, revealed by DNA laddering in agarose gels and flow cytometric analysis of annexin-V- and propidium iodide-stained cells. Treatment of HL-60 cells caused vacuolisation, partial substrate adherence, and the appearance of multi-lobed nuclei, suggesting the induction of a differentiation pathway. Vacuolisation was also observed in a human lung cancer cell line (H441). Opening of the pyranose ring of peloruside by sodium borohydride reduction increased the 48 h IC50 value by 26-fold in 32D cells, suggesting a similar active site to that proposed for bryostatin. However, unlike bryostatin, peloruside failed to bind to PKC in HL-60 cells and was unable to synergize with the calcium ionophore, ionomycin, or with interleukin-2, to activate T-lymphocytes in culture. In summary, although structurally similar to bryostatin, peloruside is a potent inhibitor of cell proliferation, has apoptosis-inducing properties and has a unique mode of action independent of PKC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11962513

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  9 in total

1.  An enantioselective synthesis of the C1-C9 segment of antitumor macrolide peloruside A.

Authors:  Arun K Ghosh; Jae-Hun Kim
Journal:  Tetrahedron Lett       Date:  2003-04-24       Impact factor: 2.415

2.  Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A.

Authors:  Ariane Chan; Connie Gilfillan; Nikki Templeton; Ian Paterson; Peter T Northcote; John H Miller
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

3.  Synthetic studies of microtubule stabilizing agent peloruside A: an asymmetric synthesis of C10-C24 segment.

Authors:  Arun K Ghosh; Jae-Hun Kim
Journal:  Tetrahedron Lett       Date:  2003-09-13       Impact factor: 2.415

4.  Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A.

Authors:  Ariane Chan; A Jonathan Singh; Peter T Northcote; John H Miller
Journal:  Invest New Drugs       Date:  2015-03-31       Impact factor: 3.850

Review 5.  Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.

Authors:  Carlo Ballatore; Kurt R Brunden; Donna M Huryn; John Q Trojanowski; Virginia M-Y Lee; Amos B Smith
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

Review 6.  Strategies for the synthesis of the novel antitumor agent peloruside A.

Authors:  David R Williams; Partha P Nag; Nicolas Zorn
Journal:  Curr Opin Drug Discov Devel       Date:  2008-03

Review 7.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

8.  Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.

Authors:  Anja Wilmes; Pisana Rawson; Lifeng Peng; Danyl McLauchlan; Peter T Northcote; T William Jordan; John H Miller
Journal:  Invest New Drugs       Date:  2010-01-27       Impact factor: 3.850

9.  Total synthesis of (-)-2-epi-peloruside A.

Authors:  Amos B Smith; Jason M Cox; Noriyuki Furuichi; Craig S Kenesky; Junying Zheng; Onur Atasoylu; William M Wuest
Journal:  Org Lett       Date:  2008-12-18       Impact factor: 6.005

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.